Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Flibanserin is a drug that is currently being investigated by Boehringer Ingelheim as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). HSDD is the most commonly reported female sexual complaint and characterized by a decrease in sexual desire that causes marked personal distress and/or personal difficulties. According to prevalence studies about 1 in 10 women reported low sexual desire with associated distress, which may be HSDD. The neurobiological pathway of female sexual desire involves interactions among multiple neurotransmitters, sex hormones and various psychosocial factors.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.